WO2001010454B1 - Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection - Google Patents
Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infectionInfo
- Publication number
- WO2001010454B1 WO2001010454B1 PCT/US2000/021462 US0021462W WO0110454B1 WO 2001010454 B1 WO2001010454 B1 WO 2001010454B1 US 0021462 W US0021462 W US 0021462W WO 0110454 B1 WO0110454 B1 WO 0110454B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- compounds
- inhibitor compounds
- reverse transcriptase
- ribonucleotide reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002346063A CA2346063A1 (en) | 1999-08-06 | 2000-08-07 | Composition and methods for treatment of hiv infection |
JP2001514970A JP2003506409A (en) | 1999-08-06 | 2000-08-07 | Compositions and methods for treating HIV infection |
AU68944/00A AU6894400A (en) | 1999-08-06 | 2000-08-07 | Composition and methods for treatment of HIV infection |
EP00957306A EP1143990A3 (en) | 1999-08-06 | 2000-08-07 | Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections |
HK02102802.2A HK1041444A1 (en) | 1999-08-06 | 2002-04-13 | Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/370,390 US6689762B1 (en) | 1998-02-09 | 1999-08-06 | Composition and methods for treatment of HIV infection |
US09/370,390 | 1999-08-06 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2001010454A2 WO2001010454A2 (en) | 2001-02-15 |
WO2001010454A3 WO2001010454A3 (en) | 2002-01-24 |
WO2001010454B1 true WO2001010454B1 (en) | 2002-07-11 |
WO2001010454A9 WO2001010454A9 (en) | 2002-11-07 |
Family
ID=23459436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/021462 WO2001010454A2 (en) | 1999-08-06 | 2000-08-07 | Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1143990A3 (en) |
JP (1) | JP2003506409A (en) |
AU (1) | AU6894400A (en) |
CA (1) | CA2346063A1 (en) |
HK (1) | HK1041444A1 (en) |
WO (1) | WO2001010454A2 (en) |
ZA (1) | ZA200102506B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100544718C (en) * | 2001-04-20 | 2009-09-30 | 维奥恩药品公司 | The purposes of chemical compound in the preparation antiviral agent |
EP1744761A4 (en) * | 2004-04-28 | 2010-01-13 | Molecules For Health Inc | Methods for treating or preventing restenosis and other vascular proliferative disorders |
EP2030615A3 (en) | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
US9556216B2 (en) | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
PL3466934T3 (en) * | 2016-05-31 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compounds or salt thereof as ribonucleotide reductase inhibitors for treating cancer |
CN111386260B (en) * | 2017-11-29 | 2024-04-30 | 大鹏药品工业株式会社 | Sulfonamide compounds and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2600256B1 (en) * | 1986-06-19 | 1988-09-16 | Inst Nat Sante Rech Med | DRUG AND DRUG COMPOSITION FOR THE TREATMENT OF TUMORS AND FOR THE TREATMENT OF VIRUS-INFECTIOUS DISEASES |
ATE265226T1 (en) * | 1997-06-09 | 2004-05-15 | Los Angeles Childrens Hospital | USE OF WOLINELLA SUCCINOGENES ASPARAGINASE FOR THE TREATMENT OF ASPARAGINE-DEPENDENT DISEASES |
DE69909747T2 (en) * | 1998-02-09 | 2004-04-15 | Enzon Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS |
-
2000
- 2000-08-07 JP JP2001514970A patent/JP2003506409A/en active Pending
- 2000-08-07 CA CA002346063A patent/CA2346063A1/en not_active Abandoned
- 2000-08-07 ZA ZA200102506A patent/ZA200102506B/en unknown
- 2000-08-07 EP EP00957306A patent/EP1143990A3/en not_active Withdrawn
- 2000-08-07 AU AU68944/00A patent/AU6894400A/en not_active Abandoned
- 2000-08-07 WO PCT/US2000/021462 patent/WO2001010454A2/en not_active Application Discontinuation
-
2002
- 2002-04-13 HK HK02102802.2A patent/HK1041444A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001010454A3 (en) | 2002-01-24 |
HK1041444A1 (en) | 2002-07-12 |
WO2001010454A9 (en) | 2002-11-07 |
AU6894400A (en) | 2001-03-05 |
JP2003506409A (en) | 2003-02-18 |
EP1143990A2 (en) | 2001-10-17 |
ZA200102506B (en) | 2002-03-27 |
EP1143990A3 (en) | 2002-03-27 |
WO2001010454A2 (en) | 2001-02-15 |
CA2346063A1 (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2145235C1 (en) | Human interferon-containing therapeutic composition, interferon-base pharmaceutical preparation (variants) | |
RU2440822C2 (en) | Methods and pharmaceutical compositions for treatment and prevention of hepatitis c infection | |
DE60018273T2 (en) | PEGYLATED INTERFERON ALPHA IN COMBINATION WITH A CCR5 ANTAGONIST FOR AN HIV THERAPY | |
EP1792915A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
FI893783A (en) | A process for the preparation of a pharmaceutical preparation for the treatment of diabetes mellitus | |
WO2001010454B1 (en) | Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection | |
JPS62246520A (en) | Prevention and reversal for cataract and ophthalmic composition | |
JPH1017466A (en) | Absorption promoter for intestinal juice | |
ES2203072T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS. | |
JP2002502826A5 (en) | ||
KR100484695B1 (en) | Pharmaceutical Compositions | |
WO1997045127A1 (en) | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders | |
US6689762B1 (en) | Composition and methods for treatment of HIV infection | |
BRPI0415322A (en) | antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life | |
US11278514B2 (en) | Composition compromising dunnione as effective ingredient for prevention or alleviation of hair loss | |
Schiedermayer | Christmas on the AIDS Ward | |
James | D4T: new clinical data confirms benefit | |
JP2005035913A (en) | Remedy against virus having plus strand rna in genetic information | |
Smith | HIV treatment options | |
Miller | New ways to take old drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000957306 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/02506 Country of ref document: ZA Ref document number: 200102506 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2346063 Country of ref document: CA Ref country code: CA Ref document number: 2346063 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 514970 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 68944/00 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2000957306 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000957306 Country of ref document: EP |